Loading ...
Sorry, an error occurred while loading the content.

Human Genome Sciences Initiates Phase 2 Clinical Trial of Albuferon(TM) for the

Expand Messages
  • Patricia (Alley)
    Human Genome Sciences Initiates Phase 2 Clinical Trial of Albuferon(TM) for the Treatment of Chronic Hepatitis C Wednesday May 26, 8:20 am ET ROCKVILLE, Md.,
    Message 1 of 1 , May 27 2:17 PM
    • 0 Attachment
      Human Genome Sciences Initiates Phase 2 Clinical Trial of Albuferon(TM) for the Treatment of Chronic Hepatitis C
      Wednesday May 26, 8:20 am ET


      ROCKVILLE, Md., May 26 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI - News) announced today that it has begun dosing patients in a Phase 2 clinical trial of Albuferon(TM) (albumin-interferon alpha) in patients with chronic hepatitis C who are naive to interferon-alpha treatments.
      http://biz.yahoo.com/prnews/040526/dcw013_1.html

      [Non-text portions of this message have been removed]
    Your message has been successfully submitted and would be delivered to recipients shortly.